A nurse holds a syringe containing a vaccine containing coronavirus (COVID-19), made by the Beijing Institute of Biological Products, a unit of the Sinopharm subsidiary China National Biotec Group (CNBG), at a vaccination center during a government visit to Beijing. , China, 15 April 2021. REUTERS / Thomas Peter
The World Health Organization will decide late this month or in May on emergency use lists for COVID-19 vaccines from Sinopharm (1099.HK) and Sinovac (SVA.O) after an extensive investigation, a WTO European official said on Thursday.
“We are in contact with them to review the dossiers submitted by both vaccine manufacturers,” Siddhartha Datta, WHO Europe Information Specialist, said at a virtual press conference. “We will hear about a decision on emergency list use in April or early May, so keep an eye on it.”
A WHO panel in the final stages of reviewing the Chinese vaccines said a decision for at least one could come on April 26, while a second meeting is scheduled for May 3, more time would be needed to decided to take both shots.
Such an emergency list from the WTO is a prerequisite for the purchase of the COVAX vaccine sharing facility designed to get shots to poorer countries. It also helps guide countries with less developed regulatory systems on the safety and efficacy of a vaccine.
So far, the WHO has issued emergency lists for Pfizer and BioNTech (22UAy.DE)’s COVID-19 vaccine, as well as versions of AstraZeneca (AZN.L), made by the Serum Institute of India and AstraZeneca-SKBio in South Korea is.
The CanSino vaccine relies on a viral vector to deliver DNA to elicit an immune response, a technique similar to that used in both AstraZeneca and Johnson & Johnson (JNJ.N) vaccines currently being tested for their associated with very rare blood clots in combination with low platelets. count.
CanSino said there were no reports of blood clots. read more
The vaccination of Sinovac, which is used in places like Hong Kong and Brazil, is dependent on inactivated coronaviruses to generate an immune response, a technique that has been used for decades, including against polio. read more
Our standards: the principles of the Thomson Reuters Trust.